IVIG Therapy: How Different IVIG Products Compare

For patients starting IVIG therapy, one of the most common questions is: aren’t all IVIG products basically the same?

The short answer is no. All IVIG products provide human immunoglobulin G (IgG), but they are not identical. Different products can vary in FDA-approved indications, concentration, excipients or stabilizers, IgA content, infusion parameters, and payer or site-of-care access. That is one reason a patient may do well on one product and need extra consideration before switching to another. FDA’s immune globulin listings show multiple licensed IVIG products, including Privigen, Gamunex-C, Gammagard Liquid, Panzyga, Octagam, Asceniv, Bivigam, Gammaplex, Flebogamma, and others.

At Vital Care of Portland, we help patients and referring providers navigate IVIG therapy with attention to product access, infusion experience, and care coordination across Oregon.

What is IVIG therapy?

IVIG, or intravenous immunoglobulin, is a plasma-derived therapy made primarily of IgG antibodies. Different IVIG products are approved for different uses. Depending on the product, FDA-approved indications may include primary humoral immunodeficiency (PI) and, for some brands, additional uses such as chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), or other labeled indications. For example, the FDA’s Privigen page lists PI, chronic ITP in patients age 15 and older, and CIDP in adults; the Panzyga labeling includes PI, ITP, and CIDP in adults; and Gammagard Liquid is labeled for PI.

That means the “right” IVIG product is not always interchangeable from a clinical or access standpoint.

Why IVIG products are not all the same

Patients and providers often think about IVIG as one therapy category, but there are meaningful differences from product to product.

1. FDA-approved indications can differ

Not every IVIG product carries the same labeled indications. Some are approved only for primary immunodeficiency, while others also have approvals for conditions such as CIDP, ITP, or other disease states. The FDA’s immune globulin listings and individual product pages make those differences clear.

For a referring provider, this matters because the product choice may need to align with the diagnosis being treated, the payer’s preferred brand, and the patient’s prior treatment history.

2. Concentration may affect infusion logistics

IVIG products are available in different concentrations, commonly 5% or 10% liquid formulations, depending on the brand. For example, Panzyga is a 10% IVIG product, Flebogamma is available in both 5% and 10% formulations, and Gamunex-C is a 10% product.

In practice, concentration can affect:

• total infusion volume

• chair time or home infusion logistics

• how the infusion is tolerated

• nursing workflow and scheduling

3. Stabilizers and excipients are not identical

One of the most important practical differences between IVIG products is the stabilizer or excipient profile. FDA labeling is the best source for confirming the exact formulation of a specific brand.

This matters because a patient’s clinical history may make one formulation more appropriate than another.

4. IgA content and patient-specific considerations may matter

Some patients have product-specific considerations related to IgA content, prior infusion reactions, renal risk, thrombotic risk, hydration status, migraine history, or other tolerability issues. IVIG product labeling carries boxed or highlighted warnings regarding thrombosis and, for some products, renal dysfunction or acute renal failure, with risk factors such as advanced age, hyperviscosity, cardiovascular risk factors, indwelling catheters, and dehydration noted in labeling.

That does not mean one product is universally safer. It means product selection should be individualized.

5. Infusion rates and administration parameters differ

Each IVIG product has its own prescribing information, including starting infusion rates, titration instructions, and maximum infusion rates as tolerated.

For patients who have experienced headaches, chills, fatigue, or prior infusion reactions, the infusion plan may need to be adjusted even when the product stays the same.

6. Insurance access and site-of-care rules often drive the real-world choice

In real-world infusion practice, the selected IVIG product is often influenced by:

• payer formulary preference

• white-bagging or specialty pharmacy carve-outs

• home infusion vs infusion suite requirements

• network access

• diagnosis-specific authorization requirements

So even when multiple products could be clinically reasonable, the therapy that is actually available to the patient may depend on access and benefit design.

What patients should know before switching IVIG products

A product switch should not feel casual. Even within the same therapy class, a switch may involve changes in:

• formulation

• infusion rate

• premedication strategy

• hydration recommendations

• monitoring needs

• insurance authorization

Patients who have been stable on a specific product often want to understand why a change is being requested and whether the new product has meaningful differences.

What providers often consider when choosing an IVIG product

Referring providers and infusion teams often look at the full picture:

• the patient’s diagnosis

• the product’s FDA-approved indication

• prior response and tolerability

• excipient profile

• site-of-care requirements

• payer preference

• nursing and infusion logistics

That is why “all IVIG is the same” is usually not the best way to think about treatment planning.

IVIG support in Oregon

At Vital Care of Portland, we work with referring providers and patients to support IVIG therapy across Oregon. That includes helping navigate:

• product access

• benefit review

• home infusion and infusion suite options

• coordination with the prescribing specialist

• patient-specific infusion considerations

Our goal is to make IVIG therapy more manageable, more coordinated, and more patient-centered.

When a product-specific conversation matters

A more detailed product discussion may be especially important when a patient:

• has had a prior infusion reaction

• has done well on one specific IVIG brand

• has renal or thrombotic risk factors

• needs a diagnosis-specific authorization

• is being forced to switch because of insurance

• needs home infusion and limited-distribution or payer rules affect access

Talk with your infusion team about IVIG product differences

If you or a loved one has questions about IVIG therapy, product selection, or home infusion options in Oregon, Vital Care of Portland can help coordinate the next step with your specialist.

Contact our team to learn more about IVIG support, infusion logistics, and access pathways in Portland and across Oregon.

FAQ section

Are all IVIG products the same?

No. IVIG products all provide IgG antibodies, but they can differ by FDA-approved indication, concentration, stabilizers or excipients, infusion instructions, and practical access considerations.

What are examples of IVIG products?

FDA-listed IVIG products include Privigen, Gamunex-C, Gammagard Liquid, Panzyga, Octagam, Bivigam, Asceniv, Gammaplex, and Flebogamma, among others.

Why might one IVIG product be chosen over another?

Providers may consider the diagnosis, FDA labeling, prior tolerability, excipient profile, infusion rate parameters, payer preference, and site-of-care restrictions. Product labeling and payer access both play a role.

Can insurance force a switch from one IVIG product to another?

Sometimes yes. Insurance formularies, specialty pharmacy carve-outs, and site-of-care rules may affect which product is accessible in practice.

Do IVIG products have different infusion rates?

Yes. Each product has its own prescribing information with specific starting rates, titration guidance, and maximum rates as tolerated.